… surgical procedures, testing may be indicated. The aim of this study was to assess findings
of haemostasis laboratory tests for one of the DOACs, dabigatran (Pradaxa), tested across a …

… (s) should be used to measure the pharmacodynamic effects of dabigatran among a range
of routine or specific tests. Testing solutions of dabigatran used in this paper were chosen to …

… and Quick PT INR>2 or Owren PT INR>1.5 over-dosing or accumulation of dabigatran …
assay group, display variable effects at therapeutic concentrations of dabigatran. Some of these …

… In summary, dabigatran demonstrates an inhibitor effect in the hemostasis laboratory and
shows clinically significant interference in various clot-based and factor IIa–based chro-…

… When we assessed the potential association between dabigatran levels (as determined by
the HTI assay) and hemostatic parameters, we detected very strong positive correlations with …

… dabigatran might affect shear-induced thrombi (occlusion time [OT], sec) by the GTT, and to
investigate the possibility that the GTT could be useful as a monitoring system for dabigatran. …

… hemostasis, may be used as a readily available screening test sensitive for the anticoagulant
effect of dabigatran … non-bleeding NVAF patients while displaying whole blood hemostasis. …

… of the effect of dabigatran on coagulation assays is based on the analysis of dabigatran-…
ex vivo samples (ie plasma from patients receiving dabigatran) in contrast to in vitro plasma …

… increasing dabigatran concentrations. Commercial TT methods were very sensitive to low
concentrations of dabigatran, with 9 of 10 reporting sites exceeding test limits at dabigatran …

… where complete haemostasis may be required dabigatran etexilate should be stopped 2–4
days before surgery. *Table 2 provides guidance for discontinuation of dabigatran etexilate …